Literature DB >> 8663146

The mammalian immediate-early TIS21 protein and the leukemia-associated BTG1 protein interact with a protein-arginine N-methyltransferase.

W J Lin1, J D Gary, M C Yang, S Clarke, H R Herschman.   

Abstract

The TIS21 immediate-early gene and leukemia-associated BTG1 gene encode proteins with similar sequences. Two-hybrid analysis identified a protein that interacts with TIS21 and BTG1. Sequence motifs associated with S-adenosyl-L-methionine binding suggested this protein might have methyltransferase activity. A glutathione S-transferase (GST) fusion of the putative methyltransferase modifies arginine residues, in appropriate protein substrates, to form NG-monomethyl and NG,NG-dimethylarginine (asymmetric). We term the protein- arginine N-methyltransferase (EC 2.1.1.23) gene "PRMT1, " for protein-arginine methyltransferase 1. GST-TIS21 and GST-BTG1 fusion proteins qualitatively and quantitatively modulate endogenous PRMT1 activity, using control and hypomethylated RAT1 cell extracts as methyl-accepting substrates. PRMT1 message appears ubiquitous, and is constitutive in mitogen-stimulated cells. Modulation of PRMT1 activity by transiently expressed regulatory subunits may be an additional mode of signal transduction following ligand stimulation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8663146     DOI: 10.1074/jbc.271.25.15034

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  143 in total

1.  Crystal structure of the conserved core of protein arginine methyltransferase PRMT3.

Authors:  X Zhang; L Zhou; X Cheng
Journal:  EMBO J       Date:  2000-07-17       Impact factor: 11.598

2.  Structure of the predominant protein arginine methyltransferase PRMT1 and analysis of its binding to substrate peptides.

Authors:  Xing Zhang; Xiaodong Cheng
Journal:  Structure       Date:  2003-05       Impact factor: 5.006

3.  Effects of a novel arginine methyltransferase inhibitor on T-helper cell cytokine production.

Authors:  Kevin Bonham; Saskia Hemmers; Yeon-Hee Lim; Dawn M Hill; M G Finn; Kerri A Mowen
Journal:  FEBS J       Date:  2010-03-22       Impact factor: 5.542

Review 4.  Histone arginine methylation.

Authors:  Alessandra Di Lorenzo; Mark T Bedford
Journal:  FEBS Lett       Date:  2010-11-11       Impact factor: 4.124

5.  Activity-based protein profiling of protein arginine methyltransferase 1.

Authors:  Obiamaka Obianyo; Corey P Causey; Justin E Jones; Paul R Thompson
Journal:  ACS Chem Biol       Date:  2011-08-23       Impact factor: 5.100

Review 6.  Small Molecule Inhibitors of Protein Arginine Methyltransferases.

Authors:  Hao Hu; Kun Qian; Meng-Chiao Ho; Y George Zheng
Journal:  Expert Opin Investig Drugs       Date:  2016-02-16       Impact factor: 6.206

7.  The Ca2+-induced methyltransferase xPRMT1b controls neural fate in amphibian embryo.

Authors:  Julie Batut; Laurence Vandel; Catherine Leclerc; Christiane Daguzan; Marc Moreau; Isabelle Néant
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-07       Impact factor: 11.205

8.  Protein methyltransferase 2 inhibits NF-kappaB function and promotes apoptosis.

Authors:  Lakshmanan Ganesh; Takanobu Yoshimoto; Narayani C Moorthy; Wataru Akahata; Manfred Boehm; Elizabeth G Nabel; Gary J Nabel
Journal:  Mol Cell Biol       Date:  2006-05       Impact factor: 4.272

9.  Protein-arginine methyltransferase 1 (PRMT1) methylates Ash2L, a shared component of mammalian histone H3K4 methyltransferase complexes.

Authors:  Jill S Butler; Cecilia I Zurita-Lopez; Steven G Clarke; Mark T Bedford; Sharon Y R Dent
Journal:  J Biol Chem       Date:  2011-02-01       Impact factor: 5.157

10.  Methyltransferase PRMT1 is a binding partner of HBx and a negative regulator of hepatitis B virus transcription.

Authors:  Shirine Benhenda; Aurélie Ducroux; Lise Rivière; Bijan Sobhian; Michael D Ward; Sarah Dion; Olivier Hantz; Ulrike Protzer; Marie-Louise Michel; Monsef Benkirane; Oliver J Semmes; Marie-Annick Buendia; Christine Neuveut
Journal:  J Virol       Date:  2013-02-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.